Latest Search
Quote
| Back Zoom + Zoom - | ||||
|
Viva Biotech (09887.HK) to Present Two Preclinical Pipeline Research Results at AACR Annual Meeting
Recommend 0 Positive 1 Negative 0 |
||||
|
||||
|
Viva Biotech (09887.HK) announced that its two preclinical pipeline research results will be presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. The two studies respectively showcase the company's innovative research in T cell engager-drug conjugates (TDC) and dual-target ADCs, further validating the company's synergistic R&D strategy across its three core proprietary technology platforms: LeadsBody (CD3 T-Cell Engager platform), X-body (4-1BB Engager platform), and TOPiKinectics (ADC technology platform). (ca/da) Auto-translated by third-party software This translation was auto-generated by third-party software. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation. More Details
Website: www.aastocks.com |
||||
Copied to Clipboard
 |
||||
